Spyre Therapeutics, Inc. SYRE Total Equity
Total Equity at other companies
Other financials
Where this comes from
Reported directly by Spyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:StockholdersEquity.
The official record: Spyre Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Spyre Therapeutics, Inc.'s total equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Spyre Therapeutics, Inc.'s total equity?
- Spyre Therapeutics, Inc. (SYRE) reported total equity of $670.81M in Q1 2026.
- How has Spyre Therapeutics, Inc.'s total equity changed year-over-year?
- Spyre Therapeutics, Inc.'s total equity increased by 39.0% year-over-year, from $482.61M to $670.81M.
- What is the long-term trend for Spyre Therapeutics, Inc.'s total equity?
- Over 5 years (2020 to 2025), Spyre Therapeutics, Inc.'s total equity has grown at a 38.6% compound annual growth rate (CAGR), from $139.83M to $715.24M.
- What does total equity mean?
- Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.